Edition:
India

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,762.50GBp
15 Dec 2017
Change (% chg)

77.50 (+2.10%)
Prev Close
3,685.00
Open
3,670.00
Day's High
3,783.00
Day's Low
3,620.00
Volume
5,503,257
Avg. Vol
2,815,001
52-wk High
5,067.00
52-wk Low
3,435.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.54
Market Cap(Mil.): £35,231.62
Shares Outstanding(Mil.): 908.51
Dividend: 3.85
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

Roche, Shire court fight escalates over haemophilia drug

ZURICH Roche's patent dispute with London-listed Shire over the Swiss drugmaker's new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

16 Dec 2017

Roche, Shire court fight escalates over haemophilia drug

ZURICH, Dec 16 Roche's patent dispute with London-listed Shire over the Swiss drugmaker's new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

16 Dec 2017

BRIEF-Shire Says New Formulation Of Oncaspar Receives Marketing Authorization In Europe

* SHIRE PLC SAYS NEW FORMULATION OF ONCASPAR RECEIVES MARKETING AUTHORIZATION IN EUROPE FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

13 Dec 2017

BRIEF-Shire Plc Appoints ‍John Miller As Interim CFO

* SHIRE PLC SAYS ‍JOHN MILLER TO SERVE AS INTERIM CFO WITH EFFECT FROM JAN 1, 2018 UNTIL THOMAS DITTRICH COMMENCES HIS EMPLOYMENT WITH CO - SEC FILING​

08 Dec 2017

Whitbread jumps after hedge fund Sachem Head declares stake

LONDON Whitbread shares jumped more than 7 percent on Wednesday after U.S.-based hedge fund Sachem Head Capital Management declared a 3.4 percent stake in the British hotel and coffee chain operator.

07 Dec 2017

Shire in deal to develop a new way to administer hemophilia drug

Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A.

05 Dec 2017

Shire in deal to develop a new way to administer hemophilia drug

Dec 5 Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A.

05 Dec 2017

BRIEF-Shire And Rani Therapeutics enter into collaboration to evaluate use of the Rani Pill technology

* SHIRE AND RANI THERAPEUTICS ENTER INTO COLLABORATION TO EVALUATE USE OF THE RANI PILL(TM) TECHNOLOGY FOR THE ORAL DELIVERY OF FACTOR THERAPY

05 Dec 2017

UPDATE 1-Britain's FTSE recoups early losses as cyclicals recover

* Mediclinic, Spire shares fall after takeover talks fall through

20 Nov 2017

UPDATE 4-Roche haemophilia drug wins FDA nod, with a warning

* Shares in rival Shire climb 6 pct (Adds projected price of drug, company comment)

17 Nov 2017

Earnings vs. Estimates